Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Avacta Group Share Price
  4. Avacta Group Share Regulatory News
  5. Director/PDMR Shareholding

Pin to quick picksAvacta Group Regulatory News (AVCT)

Avacta Group Information

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Director/PDMR Shareholding

27 Jan 2011 07:00

RNS Number : 1537A
Avacta Group PLC
27 January 2011
Β 

ο»Ώ

27 January 2011

Β 

Avacta Group plc

Β 

("Avacta" or "the Company")

Β 

Director/PDMR Shareholding

Β 

The Company announces thatΒ yesterday Alastair Smith, Chief Executive Officer, transferred 6,956,609 ordinary shares of 0.1p each ("Ordinary Shares") to his Self Invested Pension Plan ("SIPP"). As a result of this transaction his beneficial holding remains unchanged at 51,728,296 Ordinary Shares, which represents approximately 3.16 percent of the current issued share capital of the Company.

Β 

Β 

Enquiries:

Β 

Avacta Group plc

Tel: 0844 414 0452

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

www.avacta.com

Broker

XCAP Securities Plc

John Grant/Karen Kelly/David Newton

Nominated Adviser

Grant Thornton Corporate Finance

Philip Secrett/Colin Aaronson/David Hignell

Tel: 020 7101 7070

www.xcapgroup.com

Β 

Tel: 020 7383 5100

www.grantthornton.co.uk

NexFin (Financial PR)

Nicholas Nelson

Β 

Tel: 07921 522920

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSDKADNOBKDCDB
12345678910
Date   Source Headline
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20217:00 amRNSAffiDX Lateral Flow Test Detects Delta Variant
28th Jun 202112:13 pmRNSResult of AGM
21st Jun 20212:05 pmRNSSecond Price Monitoring Extn
21st Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSAffiDX Lateral Flow Test Distribution Agreement
15th Jun 20218:00 amRNSIssue of Equity and Total Voting Rights
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:07 amRNSRegistration of AffiDX Lateral Flow Test in EU
9th Jun 20219:08 amRNSHolding(s) in Company
7th Jun 20217:00 amRNSMHRA Confirms Registration of Lateral Flow Test
1st Jun 20217:00 amRNSUpdate on Lateral Flow Test Regulatory Submissions
28th May 20217:00 amRNSResponse to speculation
25th May 202110:00 amRNSPosting of Annual Report and Notice of AGM
10th May 202110:36 amRNSAffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
6th May 20217:00 amRNSChange of Nominated Adviser
30th Apr 202112:37 pmRNSIssue of Equity
28th Apr 20215:18 pmRNSIssue of Equity
28th Apr 20214:41 pmRNSSecond Price Monitoring Extn
28th Apr 20214:36 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSFinal Results
20th Apr 202111:05 amRNSSecond Price Monitoring Extn
20th Apr 202111:00 amRNSPrice Monitoring Extension
20th Apr 20217:00 amRNSClinical validation of AffiDX Lateral Flow Test
15th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:00 amRNSNotice of Results and Investor Presentation
12th Apr 20211:30 pmRNSIssue of Equity
6th Apr 20217:00 amRNSDistribution Agreement with ABCAM plc
25th Mar 20213:01 pmRNSDirectorate Change
16th Mar 20215:08 pmRNSIssue of Equity
15th Mar 20215:22 pmRNSIssue of Equity
9th Mar 20217:00 amRNSDiagnostic Licensing Deal with Biokit
8th Mar 20217:00 amRNSRapid Antigen Test Detects SARS-CoV-2 Variants
3rd Mar 20215:14 pmRNSElectronic Communications with Shareholders
24th Feb 20217:00 amRNSBusiness Update
22nd Feb 20217:00 amRNSRe: Press Speculation
18th Feb 20217:00 amRNSPhase I CTA for AVA6000 Approved by MHRA
16th Feb 20219:05 amRNSSecond Price Monitoring Extn
16th Feb 20219:00 amRNSPrice Monitoring Extension
16th Feb 20217:00 amRNSResults of Initial Evaluation of SARS-CoV-2 LFT
8th Feb 20217:00 amRNSCommercial Partnership with Mologic
2nd Feb 20218:30 amRNSIssue of Equity
1st Feb 20217:00 amRNSAffyXell $7.3 Million Series A Financing
29th Jan 202111:00 amRNSIssue of Equity
28th Jan 20217:00 amRNSCollaboration Agreement with Bruker
7th Jan 20217:00 amRNSLicense Agreement with POINT Biopharma Inc.
5th Jan 202111:05 amRNSSecond Price Monitoring Extn
5th Jan 202111:00 amRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSSubmission of CTA for AVA6000 Pro-doxorubixin
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
BIFF
BIFF.L
LSE
0.00%
LSRG
LSRG.L
LSE
0.00%
AGK
AGK.L
LSE
0.00%
AOF
Africa Opp.
LSE
0.00%
COST
Costain Group
LSE
-1.66%
Trending
LLOY
Lloyds
LSE
-0.90%
KEFI
Kefi Gold & Copper
LSE
-4.23%
GGP
Greatland Resources
LSE
-2.84%
QHE
Quantum Helium
LSE
6.67%
80M
80 Mile
LSE
8.21%